144 related articles for article (PubMed ID: 27063172)
21. The effect of clomiphene citrate on oxidative stress parameters in polycystic ovarian syndrome.
Peker N; Turan G; Ege S; Bademkıran MH; Karaçor T; Erel Ö
J Obstet Gynaecol; 2021 Jan; 41(1):112-117. PubMed ID: 32131660
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial.
Kuek S; Wang WJ; Gui SQ
Zhong Xi Yi Jie He Xue Bao; 2011 Sep; 9(9):965-72. PubMed ID: 21906521
[TBL] [Abstract][Full Text] [Related]
23. Oxidative stress markers in the follicular fluid of patients with polycystic ovary syndrome correlate with a decrease in embryo quality.
Liu Y; Yu Z; Zhao S; Cheng L; Man Y; Gao X; Zhao H
J Assist Reprod Genet; 2021 Feb; 38(2):471-477. PubMed ID: 33216309
[TBL] [Abstract][Full Text] [Related]
24. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Martínez-Bermejo E; Lasunción MA; Escobar-Morreale HF
J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
[TBL] [Abstract][Full Text] [Related]
25. The effect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome.
Gul OB; Somunkiran A; Yucel O; Demirci F; Ozdemir I
Arch Gynecol Obstet; 2008 Jan; 277(1):25-30. PubMed ID: 17618446
[TBL] [Abstract][Full Text] [Related]
26. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate.
Armstrong VL; Wiggam MI; Ennis CN; Sheridan B; Traub AI; Atkinson AB; Bell PM
QJM; 2001 Jan; 94(1):31-7. PubMed ID: 11161134
[TBL] [Abstract][Full Text] [Related]
27. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
Falsetti L; Pasinetti E
Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
[TBL] [Abstract][Full Text] [Related]
28. Relationship between oxidative stress and clinical pregnancy in assisted reproductive technology treatment cycles.
Ozatik O; Aydin Y; Hassa H; Ulusoy D; Ogut S; Sahin F
J Assist Reprod Genet; 2013 Jun; 30(6):765-72. PubMed ID: 23666546
[TBL] [Abstract][Full Text] [Related]
29. Weight change and androgen levels during contraceptive treatment of women affected by polycystic ovary.
Vrbikova J; Dvorakova K; Hill M; Starka L
Endocr Regul; 2006 Dec; 40(4):119-23. PubMed ID: 17201585
[TBL] [Abstract][Full Text] [Related]
30. Effect of periodontal disease on oxidative stress markers in patients with atherosclerosis.
Sari A; Davutoglu V; Bozkurt E; Taner IL; Erciyas K
Clin Oral Investig; 2022 Feb; 26(2):1713-1724. PubMed ID: 34415433
[TBL] [Abstract][Full Text] [Related]
31. Oxidative stress status in Chinese women with different clinical phenotypes of polycystic ovary syndrome.
Zhang R; Liu H; Bai H; Zhang Y; Liu Q; Guan L; Fan P
Clin Endocrinol (Oxf); 2017 Jan; 86(1):88-96. PubMed ID: 27489079
[TBL] [Abstract][Full Text] [Related]
32. Paraoxonase-1 is not affected in polycystic ovary syndrome without metabolic syndrome and insulin resistance, but oxidative stress is altered.
Torun AN; Vural M; Cece H; Camuzcuoglu H; Toy H; Aksoy N
Gynecol Endocrinol; 2011 Dec; 27(12):988-92. PubMed ID: 21557696
[TBL] [Abstract][Full Text] [Related]
33. Association between CD16
Tang L; Ye J; Shi Y; Zhu X
Int J Gynaecol Obstet; 2019 Apr; 145(1):12-17. PubMed ID: 30710445
[TBL] [Abstract][Full Text] [Related]
34. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
Falsetti L; Dordoni D; Gastaldi C; Gastaldi A
Acta Eur Fertil; 1986; 17(1):19-25. PubMed ID: 2941960
[TBL] [Abstract][Full Text] [Related]
35. A randomized crossover study of medroxyprogesterone acetate and Diane-35 in adolescent girls with polycystic ovarian syndrome.
Chung JP; Yiu AK; Chung TK; Chan SS
J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):166-71. PubMed ID: 24656700
[TBL] [Abstract][Full Text] [Related]
36. [Study on the oxidative stress in the ovaries of a rat model of polycystic ovary].
Gong J; Wu DB; Zhang LL; Li J; Zhao X; Zhang D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Mar; 46(2):238-42, 247. PubMed ID: 25924437
[TBL] [Abstract][Full Text] [Related]
37. The role of oxidative stress in early-onset androgenetic alopecia.
Kaya Erdogan H; Bulur I; Kocaturk E; Yildiz B; Saracoglu ZN; Alatas O
J Cosmet Dermatol; 2017 Dec; 16(4):527-530. PubMed ID: 27987270
[TBL] [Abstract][Full Text] [Related]
38. Total Oxidant/Antioxidant Status in Sera of Patients with Esophageal Cancer.
Huang Q; Feng J; Wu R; Yang Y; Dai C; Li J; Liao Y; Xiang M; Wang D; Du XB
Med Sci Monit; 2017 Aug; 23():3789-3794. PubMed ID: 28777781
[TBL] [Abstract][Full Text] [Related]
39. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
[TBL] [Abstract][Full Text] [Related]
40. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin.
Feng W; Jia YY; Zhang DY; Shi HR
Gynecol Endocrinol; 2016; 32(2):147-50. PubMed ID: 26507097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
